European Patent Application EP4626555A1, published on March 11, 2026, by Tiger Biotherapeutics Inc., details glutarimide-containing compounds intended for use as pan-KRAS-mutant degrader agents. These compounds are specifically designed for the treatment of cancers driven by KRAS mutations, a common target in oncology research.

This patent publication signifies a new development in potential cancer therapies. While it does not impose immediate compliance obligations, it is relevant for pharmaceutical companies and drug manufacturers involved in oncology research and development. Companies operating in this space should be aware of this patent as it may impact future drug development strategies and intellectual property landscapes.